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Minocycline is cytoprotective in human corneal
endothelial cells and induces anti-apoptotic B-cell
CLL/lymphoma 2 (Bcl-2) and X-linked inhibitor of
apoptosis (XIAP)
Marcus Kernt, C Hirneiss, A S Neubauer, A Kampik
ABSTRACT
Introduction Loss of corneal endothelial cells (CECs) is
one major factor limiting transplant clarity and survival
after keratoplasty. Amongst other factors, apoptosis due
to cellular stress is responsible for these problems. This
study investigates the possible anti-apoptotic and
cytoprotective effects of minocycline on a human corneal
endothelial cell line (HCEC-SV40) cultured under
oxidative stress and with transforming growth factor
beta (TGF-b).
Methods CECs were treated with 1e150 mM
minocycline. Cell viability and the median inhibitory
concentration (IC50) were evaluated after 48 h and after
H2O2 treatment (tetrazolium dye reduction assay and
liveedead assay). Expression of B-cell CLL/lymphoma 2
(Bcl-2) and X-linked inhibitor of apoptosis (XIAP) and
their mRNA were assessed by reverse transcriptase
(RT)-PCR and western blot analysis after treatment with
minocycline alone and consecutive incubation with
200 mM H2O2 and TGF-b2. A quantitative detection of
histone-associated DNA fragmentation by ELISA was
performed.
Results Minocycline concentrations from 1e50 mM
showed no toxic effects on CECs. Pre-treatment with
10e40 mM minocycline led to an increase in viability
after H2O2 treatment. In addition, minocycline pre-
treatment attenuated the increase of histone-associated
DNA fragmentation after treatment with H2O2 and
TGF-b2 significantly. When CECs were treated with
minocycline and then consecutively with H2O2 or TGF-b2,
RT-PCR and western blot analysis yielded an
overexpression of Bcl-2 and XIAP.
Conclusion In this study minocycline prevented
apoptotic cell death in cultured CECs in vitro. Our results
suggest that minocycline might offer cytoprotective
properties that might help to prevent loss of corneal
endothelial cells in vivo.
INTRODUCTION
Corneal transparency is a major prerequisite for
normal vision. The corneal endothelium, which is
comprised of a single layer of cells of neural crest
origin, maintains the osmotic homeostasis of the
cornea and is essential for ensuring corneal clarity.1
Therefore, a healthy endothelium is essential. Unlike
in other mammalian species, the capacity of the
human corneal endothelium for regeneration after
injury is severely limited.2 3 In general, wound repair
and cell loss are achieved by the enlargement and
migration of the surrounding cells.2 3 The normal
endothelial cell count is about 3000 cells/mm2 in
young adults and decreases to approximately
2000 cells/mm2 during the lifetime.4 Although there
is no exact threshold, a cell density less than
400e800 cells/mm2 often produces corneal opacity
through inadequate corneal hydration.1 Corneal
opacities due to endothelial cell loss are commonly
irreversible. In such cases, keratoplasty is often the
only therapeutic option to improve vision.5
One major quality criterion for donor corneas for
transplantation is the endothelial cell count and the
success of corneal transplantation depends at least
in part on a healthy endothelium in the donor
cornea.5 It has been demonstrated that the deteri-
oration of the corneal endothelium in donor
corneas for transplantation occurs more frequently
with increasing length of organ culture time and
leads to cell loss.6 7 This results in an increased
susceptibility of cells.
Reactive oxygen species (ROS) intermediates and
oxidative stress are thought to induce apoptotic cell
death and have been implicated in the progression
of ageing.8 Among various causes, oxidant species
and oxidative stress are considered to be cytotoxic,
and it has been suggested that they are responsible
for corneal cell death.9 There is evidence that the
loss of endothelial cells is at least partly due to
apoptosis.10
Apart from this, many models have shown that
apoptotic cell death is a result of changes in environ-
mental stimuli, such as growth factors. The trans-
forming growth factor beta (TGF-b) family includes
three multifunctional proteins, TGF-b1, TGF-b2
and TGF-b3, that are found in aqueous humour.11
TGF-b is involved in regulating cell differentia-
tion, cell proliferation and other cell functions.12
Altered levels of TGF-b have been reported in
several ocular conditions and pathologies such as
uveitis, glaucoma or diabetes, and are considered to
be pro-apoptotic.11 13e15 In addition, it has been
demonstrated that the activity of TGF-b is related to
the production of hydrogen peroxide (H2O2) and
induces oxidative stress in lens epithelial cells.16
TGF-b2, the isoform of TGF-b most strongly
expressed in human eyes, reportedly inhibits
the proliferation of corneal endothelial cells.17 18
Furthermore, TGF-b2 stimulates prostaglandin
synthesis in corneal endothelium and inhibits its
proliferation in a dose-dependent manner.18
Minocycline is a semi-synthetic, second-genera-
tion tetracycline. It is cheap, widely available and
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has proven its safety and its beneficial antimicrobial and anti-
inflammatory actions for many years.19 In addition, minocycline
has recently been demonstrated to have cytoprotective proper-
ties in several cellular systems, and in models for neurodegen-
erative and retinal disease.20e23 The present study evaluated
whether minocycline at various concentrations has toxic effects
on cultivated human corneal endothelial cells (CECs). In addi-
tion, we investigated the effects of minocycline on viability,
induction of cellular death and apoptosis in CECs. To elucidate
the potential protective and anti-apoptotic effects of mino-
cycline, the expression of two anti-apoptotic proteins, B-cell
CLL/lymphoma 2 (Bcl-2) and X-linked inhibitor of apoptosis
(XIAP) and their mRNA were quantified.
METHODS
Minocycline was obtained as lyophilised powder (Sigma-Aldrich,
St Louis, Missouri, USA) and reconstituted with sterile water to
obtain a 1 mM stock solution. This stock solution was then
further diluted in a 1:1 mixture of M199/F12 medium (M199/
F12; Biochrom, Cambridge, UK) to obtain the final concentra-
tions of 1, 5, 7.5, 10, 15, 20, 40, 50, 75, 100 and 150 mM.
Human corneal endothelial cells
Immortalised, cultured human CECs from a well established cell
line (HCEC-SV40) were provided by Professor J Bednarz
(University of Hamburg, Klinikum Eppendorf, Hamburg,
Germany).24 CECs were grown in a 1:1 mixture of M199/F12
medium (Biochrom, Cambridge, UK) supplemented with 5%
fetal calf serum and without addition of antibiotics.
Cell culture treatment
For all cell culture experiments, CECs (23105 cells/well) were
seeded in 35-mm diameter tissue culture dishes and exposed to
minocycline concentrations (1e150 mM). For exposure to the
various concentrations of minocycline, the CECs were kept for
24 h in serum-free conditions. After the cells were washed with
phosphate buffered saline (PBS), they were incubated for 24 h
with various concentrations of minocycline dissolved in a 1:1
mixture of M199/F12 medium for CECs. Then the serum-free
medium containingminocyclinewas removed by carefully rinsing
the cells with serum-free medium three times. After another 24 h
of incubation with serum-free medium, cell viability assay, RNA
isolation or protein extraction was performed.
For testing the various concentrations of minocycline under
conditions of oxidative stress, the cells were treated for 24 h
with the two tested concentrations of minocycline (15 and
20 mM), and then 200 mM H2O2 was added for 4 h.
In unpublished pilot work in our laboratory several concentra-
tions of H2O2 and different treatment times were tested. The
concentration of 200 mMH2O2 and a 4-h treatment was chosen in
order toproduceanadequatedegreeof cell injury inuntreatedCECs.
The serum-free medium containing H2O2 and minocycline
was then removed by carefully rinsing the cells with serum-free
medium three times. After another 24 h of incubation with
serum-free medium, cell viability assay, RNA isolation or protein
extraction was performed.
For testing minocycline in the presence of TGF-b2, cells were
treated for 24 h with the various concentrations of minocycline
(15 and 20 mM) and then 1 ng/ml TGF-b2 was added. After
another 24 h of incubation with minocycline and TGF-b2, RNA
isolation or protein extraction was performed.
MTT assay
Tetrazolium dye-reduction assay (MTT; 3-[4,5-dimethylthiazol-
2-yl]-2,5-diphenyl tetrazolium bromide) was used to determine
the cell survival rate. The MTTassay was performed as described
in the literature by Mosmann25 with some modifications. The
medium was removed, cells were washed with PBS, and 2000 ml/
well MTT solution (1.5 ml MTT stock, 2 mg/ml in PBS, plus
28.5 ml Dulbecco’s modified Eagle’s medium (DMEM)) was
added. CECs were incubated at 378C for 1 h. Formazan crystals
that formed were dissolved by the addition of dimethylsulfoxide
(DMSO; 1000 ml/well). Absorption was measured by a scanning
multiwell spectrophotometer at 550 nm (Molecular Probes,
Garching, Germany). The results were expressed as the mean
percentage of the control viability. Experiments were performed
in triplicate and repeated three times. CECs from the same
passage, incubated with balanced saline without the addition of
other substances, served as the control. For all experiments,
stationary cell cultures were used. The MTT test, as performed
in our study, is a well established test for assessment of cell
viability.
Liveedead cell viability assay
Confluent CECs were prepared and treated as described above.
Cell viability was quantified based on a two-colour fluorescence
assay. The nuclei of non-viable cells appear red because of
staining by the membrane-impermeable dye propidium iodide
(Sigma-Aldrich), whereas the nuclei of all cells were stained with
the membrane-permeable dye Hoechst 33342 (Intergen;
Purchase, New York, USA). Confluent cultures of CECs growing
on coverslips in 35-mm tissue culture dishes were exposed to the
various concentrations of minocycline as described for the MTT
assay. For the evaluation of cell viability, the cells were washed
in PBS and incubated with 2.0 mg/ml propidium iodide and
1.0 mg/ml Hoechst 33342 for 20 min at 378C. Subsequently, the
cells were analysed with an epifluorescence microscope
(Aristoplan; Leitz, Wetzlar, Germany). The labelled nuclei were
then counted in fluorescence photomicrographs, and dead cells
were expressed as a percentage of the total nuclei in the field.
Data (mean6SD) are based on the sampling of six to 10
photomicrographs per condition in three independent experi-
ments performed in duplicate. The percentage of dead cells was
scored by counting at least 500 cells in fluorescence photomi-
crographs of representative fields. CECs of the same passage
served as the control.
Detection of apoptosis
Apoptosis is characterised by membrane blebbing, condensation
of cytoplasm and the activation of endogenous endonucleoses.
This leads to internucleosomal cleavage of DNA and the gener-
ation of mono- and oligonucleosomes, which are tightly
complexed with histones. To quantify apoptosis in CECs,
quantitative detection of histone-associated DNA fragments in
mono- and oligonucleosomes, a marker for apoptosis, was
performed by an ELISA. CECs were treated with minocycline
and 200 mM H2O2 or TGF-b2 as described before. Cells were
then collected from culture dishes and subjected to a cell death
detection ELISA (Roche Applied Science, Indianapolis, Indiana,
USA).
RNA isolation and real-time PCR
The total RNA for Bcl-2 and XIAP detection was isolated from
35-mm tissue culture dishes by the guanidium thio-
cyanateephenolechloroform extraction method. Quantification
of Bcl-2 and XIAP mRNA was performed by reverse transcrip-
tase (RT)-PCR using a LightCycler Instrument (LightCycler
System, Roche Diagnostics, Germany) according to previous
descriptions.26 The levels of Bcl-2 and XIAP mRNA were
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determined as a relative ratio (RR), which was calculated by
dividing the level of Bcl-2 and XIAP mRNA by the level of the
18S rRNA housekeeping gene in the same samples. All experi-
ments were performed at least in triplicate and repeated three
times. The primers used for RT-PCR are shown in table 1.
Protein extraction and western blot analysis of Bcl-2 and XIAP
CECs grown on 35-mm tissue culture dishes were washed twice
with ice-cold PBS, collected, and lysed in RIPA cell lysis buffer.
After centrifugation for 30 min at 19 000 g in a microfuge
(5810R; Eppendorf, Hamburg, Germany) in the cold, the
supernatant fraction was transferred to fresh tubes and stored at
708C for future use. The protein content was measured by the
bicinchoninic acid (BCA) protein assay (Pierce, Rockford, Illi-
nois, USA). Denatured proteins (1.2 mg) were separated under
reducing conditions by electrophoresis using a 5% SDSepolya-
crylamide stacking gel and a 12% SDSepolyacrylamide sepa-
rating gel, transferred with semi-dry blotting onto a polyvinyl
difluoride membrane (Roche Diagnostics), and probed with
a mouse anti-Bcl-2-antibody or a mouse anti-XIAP-antibody as
described previously.26 Chemiluminescence was detected with
an imager (LAS-1000; RayTest, Straubenhardt, Germany) and
generated light units (LU). The exposure times ranged between 1
and 10 min. All experiments were performed at least in tripli-
cate. Quantification of the chemiluminescence signal by densi-
tometry was performed by using a specific computer software
(AIDA; RayTest).
Statistical evaluation and expression of results
All data were analysed using SPSS 17.0 for Windows (SPSS Inc.,
Chicago, Illinois, USA). For all statistical tests, p<0.05 was
considered significant. Results of the MTTassay are presented as
mean (6SD) units of absorbance. Ten individual samples per
group were measured in triplicate. Results of the RT-PCR are
presented as mean (6SD) ratios of the investigated mRNA and
18S rRNA; all experiments were performed in triplicate and
repeated three times. Western blot analysis was performed
analogously; CEC culture experiments were performed at least
in triplicate. Analysis of variance with Bonferroni correction in
post hoc testing was applied to investigate statistical signifi-
cance of differences. To evaluate the effects of treatment with
the various concentrations of minocycline univariate ANOVA
modelling was performed, considering the factors TGF-b treat-
ment and H2O2 concentration. Post hoc testing for significant
factors applied Bonferroni correction.
RESULTS
Testing concentrations of minocycline in cultured CECs
No gross abnormalities could be detected in CECs with phase-
contrast microscopy for minocycline concentrations up to 75 mM
(data not shown). The number of cells, counted in phase-contrast
microscopy, correlated well with the results of the MTT test.
When CECs that were pre-treated with 15 or 20 mM mino-
cycline were treated with 200 mM H2O2, cells showed only very
few signs of toxicity. Control cells treated with 200 mM H2O2
that had no minocycline pre-treatment showed pronounced
morphological signs of toxicity such as abnormal shape and
appearance, cellular lysis and destruction (data not shown).
MTT assay
Minocycline concentrations between 1 and 50 mM showed no
significant toxic effects on CECs (24 h exposure). No significant
decrease in cellular viability was detected compared with the
control. Concentrations of minocycline between 75 mM
(p¼0.696) and 100 mM (p#0.001) led to a dose-dependent
reduction of viability. The concentration of minocycline that
inhibited viability by 50% (IC50) was determined from the
doseeresponse curves and for 24-h application was approxi-
mately 100 mM (66.8 CI) for CECs. The tested minocycline
concentrations of 150 mM reduced the number of viable cells to
less than 30% (figure 1).
When cells were treated with 200 mMH2O2 only, a significant
decrease in viability was detected compared with the untreated
control cells (p#0.001). In contrast, cells that were treated with
minocycline in concentrations between 10 and 40 mM and then
subsequently treated with 200 mM H2O2 showed no significant
decrease in cell viability compared with cells that were treated
with minocycline concentrations between 10 and 40 mM only.
When cells were treated with minocycline in concentrations
between 50 and 150 mM and then subsequently treated with
200 mM H2O2, a pronounced dose-dependent decrease in the
viability of cells was detected (figure 1).
Liveedead assay for corneal endothelial cells
Minocycline concentrations between 1 and 75 mM did not show
any significant effect on cell viability in CECs, either after 24 h
treatment or after additional treatment with 200 mM H2O2 for
4 h. When CECs were treated with minocycline in a concentra-
tion of 20 mM, no increase of the percentage of non-viable cells
could be detected (p¼1.0). In contrast, pre-treatment with
20 mM minocycline did reduce the number of death cells when
treated with 200 mM H2O2 for 4 h (p#0.001) compared with
controls (figure 2). High concentrations of minocycline
(>75 mM) induced a marked, dose-dependent reduction of viable
CECs (data not shown).
Table 1 Primers used for RT-PCR
Target Length Position AT (8C) % GC Sequence
Bcl-2 19 3465e3483 60 58 agaggtcacgggggctaat
20 3505e3524 60 50 ccaggtaacaaaaccccaca
XIAP 25 846e870 60 36 ttttgggacatggatatactcagtt
25 910e934 59 40 agcactttactttatcaccttcacc
AT, annealing temperature; GC, guanineecytosine content.
Figure 1 The viability of corneal endothelial cells (CECs) after 24-h
treatment with the concentrations of minocycline investigated (black
curve, diamonds) and additionally treated with 200 mM H2O2 (grey
curve, triangles), measured by a colorimetric test (MTT). x-Axis:
concentrations of minocycline tested. Error bars, SD.
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Figure 2 Corneal endothelial cells
(CECs) were treated for 24 h with
various concentrations of minocycline
only or treated with minocycline for
24 h and 200 mM H2O2 for 4 h as
described. After exposure of the cells to
the substance alone or in combination
with oxidative stress, viability was
determined by staining all nuclei with
Hoechst 33342 and dead cells with
propidium iodide. (A) Representative
fluorescence photomicrograph of
Hoechst 33342-stained, untreated CECs
as the control. (B) Non-viable cells
in the corresponding field.
(C) Fluorescence photomicrograph of
CECs treated with 20 mM minocycline
for 48 h and labelled with Hoechst
33342. (D) Non-viable CECs treated
with 20 mM for 48 h in the same field.
(E) Fluorescence photomicrograph of
CECs treated with 200 mM H2O2 only.
(F) Non-viable CECs treated with
200 mM H2O2 only in the same field.
(G) Fluorescence photomicrograph of
CECs treated with minocycline
concentrations of 20 mM for 24 h and
with 200 mM H2O2 and labelled with
Hoechst 33342. (H) Non-viable CECs
treated with minocycline
concentrations of 20 mM for 48 h and
with 200 mM H2O2 in the same field.
(AeH) White scale bar: 100 mm.
Figure 3 Inhibitory effect of
minocycline on transforming growth
factor beta (TGF-b)2- and H2O2-induced
apoptosis in corneal endothelial cells
(CECs). Histone-associated DNA
fragmentation in CECs as investigated
by an ELISA method: untreated control
(Co), CECs treated with 200 mM H2O2
(H2O2) or TGF-b2, after treatment with
15 and 20 mM minocycline (M15 and
M20) only, or after minocycline
treatment and additional treatment with
200 mM H2O2 or TGF-b2. Each value
was normalised to the mean amount of
histone-associated DNA fragments
detected in the control. Data values
are mean6SD. y-Axis: ratio of
histone-associated DNA fragmentation
of each probe normalised to
histone-associated DNA fragmentation
of the control.
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Detection of apoptosis
To investigate the effect of minocycline on apoptosis due to
200 mM H2O2 or TGF-b2 exposure in CECs, a quantitative
detection of histone-associated DNA fragments in mono-
and oligonucleosomes was conducted by using an ELISAmethod.
In our experimental set-up, both 200 mM H2O2 (p#0.001) and
TGF-b2 (p¼0.031) led to a significant increase of histone-associated
DNA fragments in cultured CECs. In contrast, when cells were
pretreated with minocycline for 24 h and then exposed to 200 mM
H2O2 or TGF-b2, minocycline treatment decreased the amount of
histone-associated DNA fragments significantly compared with
those cells that were treated withH2O2 or TGF-b2 alone (figure 3).
Expression of Bcl-2 and XIAP mRNA in CECs
Bcl-2andXIAPmRNAexpressionwasdetected in every sample.All
detectedmRNA levels of Bcl-2 and XIAPwere normalised to those
of 18S rRNA, and values are expressed as the relative ratio (RR) of
Bcl-2/18S or XIAP/18S. The findings indicate that treatment with
minocycline leads to an increased mRNA expression of both Bcl-2
and XIAP. In contrast, TGF-b2 and H2O2 treatment significantly
decreased mRNA expression of Bcl-2 and XIAP in CECs.
The cells treated with both minocycline and with TGF-b2 or
H2O2 seemed to compensate for the decrease of Bcl-2 and XIAP
mRNA expression by TGF-b2 and H2O2 reaching mRNA levels
of Bcl-2 and XIAP comparable to those of the untreated controls
or even higher. In addition, the cells pre-treated with minocy-
cline showed significantly higher levels of Bcl-2 and XIAP mRNA
in CECs than cells treated with TGF-b2 or H2O2 only (figure 4).
Protein expression of Bcl-2 and XIAP in human CECs
To verify that the decrease in Bcl-2 and XIAP under TGF-b2 and
H2O2 treatment and the minocycline-induced increase in Bcl-2
and XIAP in mRNA transcription translates into increased
protein synthesis, whole cellular protein extracts whole cellular
Figure 4 B-cell CLL/lymphoma 2
(Bcl-2) and X-linked inhibitor of
apoptosis (XIAP) mRNA expression of
corneal endothelial cells (CECs) after
24 h treatment with 15 or 20 mM
minocycline (M15 or M20) only or after
additional treatment with 200 mM H2O2
or TGF-b2, as investigated by
quantitative RT-PCR. x-Axis:
concentrations of minocycline tested;
y-axis: relative ratio (RR) of Bcl-2
mRNA normalised to 18S rRNA
expressed in decimal format.
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protein extracts of untreated CECs as the control, cells treated
with minocycline concentrations alone, and cells consecutively
treated with TGF-b2 or 200 mM H2O2, were analysed by
western blotting. An even protein load in each lane was
confirmed by the staining of the polyvinyl difluoride
membranes with Coomassie Brilliant Blue after the blotting
procedure.
Both treatment with 200 mM H2O2 and TGF-b2 treatment
decreased Bcl-2 and XIAP expression in CECs compared with the
control. CECs that were pre-treated with 20 mMminocycline and
then treated with 200 mM H2O2 showed a significantly lower
decrease of both Bcl-2 and XIAP expression compared with the
control than those cells that were treated only with H2O2. The
same effect was detected for TGF-b2 treatment. CECs that were
pre-treatedwith20 mMminocycline showeda significant increased
expression of Bcl-2 and XIAP comparedwith the control (figure 5).
DISCUSSION
Deterioration of the corneal endothelium can lead to endothelial
cell loss and irreversible opacification of the cornea. Such loss is
serious in humans as the capacity of corneal endothelial cell
regeneration is limited.2 3 Therefore, one major prerequisite for
corneal clarity is the endothelial cell count.
Apoptosis is an important mechanism of corneal endothelial
cell loss, both in physiological and pathological conditions.10 In
vitro investigations of bovine corneal endothelial cells have
demonstrated that endothelial cell apoptosis is mediated by
oxidative stress and that apoptosis is dependent on local envi-
ronmental factors.27 28 The aim of our study was to elucidate
whether the tetracycline antibiotic minocycline offers properties
to prevent apoptotic cell death and consecutive CEC loss in
a cultured human corneal endothelial cell line in vitro. The cell
line investigated does not only offer the morphological charac-
teristics of the physiological corneal endothelium in vivo, but
also possesses functional properties, such as the capacity to
regulate stromal hydration.29 The data presented might be
useful in the prevention of endothelial cell loss of cultured donor
corneas for transplantation and under certain conditions in vivo.
Minocycline is a well established and safe drug and has proven
its antimicrobial and anti-inflammatory qualities for many
years.19 In addition to its antibiotic and anti-inflammatory
activity, it has been shown to have cytoprotective characteristics
against various stimuli, including oxidative stress, ischaemia and
cytokines.22 30e32 The cytoprotective effects of minocycline
have been suggested to be anti-inflammatory and also anti-
apoptotic. Recent reports have demonstrated minocycline’s
antioxidant properties and its influence on caspases and nitric
oxide synthase activity.33 Its inhibiting effect on the release of
apoptotic proteins, such as cytochrome c and Smac/Diabolo, and
its induction of anti-apoptotic proteins, such as Bcl-2 or XIAP,
have been described in several cellular systems.20 22
Our results demonstrate that minocycline protects cultured
corneal endothelial cells from oxidative stress. We were able to
show that oxidative stress due to H2O2 leads to an increase of
cell death and apoptosis in the investigated human CEC line.
This induction of apoptotic cell death went along with
a decrease of two anti-apoptotic proteinsdBcl-2 and XIAP. In
contrast, we were able to show that minocycline is able to
attenuate this induction of cell death and that at least one
cytoprotective mechanism of minocycline is its induction of
these anti-apoptotic proteins (Bcl-2 and XIAP).
Bcl-2 is generally considered to be a custodian of mitochon-
drial functional integrity as it stabilises the mitochondrial
membrane against the release of cytochrome c. Through its
inhibitory effect on caspase activation, Bcl-2 is able to interrupt
apoptosis.34 It has been shown that Bcl-2 mediates cell survival
and decreases apoptosis in human retinal pigment epithelial cells
(RPE)35 and other ocular and non-ocular cell lines.36 37 XIAP is
another potent and well-characterised anti-apoptotic protein. It
is related to the tumour suppressor protein p35, which
suppresses the activity of the apoptosis-promoting key caspases
3, 7 and 9.38 It has been demonstrated that the overexpression of
XIAP protects injured neuronal cells and photoreceptors from
further compromise in vivo.39 40
The growth factor TGF-b is expressed by almost every cell.
Altered levels of TGF-b are associated with several ocular
pathologies, including glaucoma.14 It has been demonstrated
that both acute and chronic glaucoma can lead to endothelial
cell loss and that preoperative glaucoma is a major risk factor for
increased endothelial cell loss following keratoplasty.41 42 So
another important finding of our investigations is that TGF-b2,
the isoform of TGF-b most expressed in human eyes, induced
apoptotic cell death in human CECs. This corresponds well to
the apoptotic effects of TGF-b described previously in many
cellular systems.14 This induction of apoptosis was accompanied
by a reduction of Bcl-2 and XIAP levels in CECs. In contrast, we
were able to show that minocycline increases Bcl-2 and XIAP
expression on both the RNA level and the protein level, not only
under standard conditions but also under conditions of oxidative
stress and increased levels of TGF-b2.
Because of its antibiotic and anti-inflammatory actions,
minocycline is widely used and has proven its safety as an oral
antibiotic for many years.19 43 In our in vitro study, treatment of
CEC with minocycline in concentrations up to 50 mM under
standard conditions did not reveal significant toxicity. However,
after treatment with H2O2, doses >40 mM led to a significant
decrease in the viability of cells. In our experimental setting
minocycline concentrations of 20 mM revealed anti-apoptotic
Figure 5 Effects of minocycline-treatment on B-cell CLL/lymphoma 2
(Bcl-2) and X-linked inhibitor of apoptosis (XIAP) protein expression.
Corneal endothelial cells (CECs) were treated with 20 mM Minocycline
for 24 h only or additionally with TGF-b2 (1 ng/ml) or 200 mM H2O2.
Western blotting was used to analyse protein expression in the control
(A and G) and in treated cell extracts: TGF-b2 (B and H), 20 mM
minocycline (C and I), 20 mM minocycline and TGF-b2 (D and K),
200 mM H2O2 (E and L), and 20 mM minocycline and 200 mM H2O2 (F
and M). Protein expression in control cell extracts was set as ‘1’. The
values indicate the ratios of treated cell extracts compared with control
cell extracts. Ten micrograms of protein were loaded per lane. Even
protein load in each lane was confirmed by Coomassie Brilliant Blue
staining of the polyvinyl difluoride membranes.
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effects. This would correspond to an estimated dose of
approximately 750 mg/day in human adults, which is
undoubtedly a high dosage.19 44 45 On the other hand, previous
reports have shown that daily tetracyclin doses >2000 mg are
still relatively safe in healthy pregnant women19 Our results
from cell culture experiments seem to indicate that minocycline
protects the corneal endothelium from two potential apoptotic
stimuli. In addition, minocycline increases the expression of two
anti-apoptotic proteins in cultured CECs. Even if the therapeutic
range of minocycline in our setting was limited, it might be
worthwhile to further investigate minocycline’s anti-apoptotic
and cyto-protective effects on the corneal endothelium.
The CECs we used for our experiments have demonstrated
morphological characteristics of the physiological corneal
endothelium in vivo, but also possess functional properties, such
as the capacity to regulate stromal hydration.29 Nevertheless,
one major limitation of our study might be that the cells we
used for our experiments were from an immortalised, cultured
cell line with all its limitations, and our results cannot be
directly transferred in vivo. In addition, it is not clear that the
cytoprotective effect of minocycline seen after short-term
exposure also occurs after long-term exposure.
Nevertheless, our findings indicate that minocycline might
offer cytoprotective properties that could help to increase corneal
endothelial cell survival and resistance to stress as it occurs under
certain pathological conditions and ocular disease.9 The anti-
apoptotic, cytoprotective effects of minocycline described here
may provide a basis for the prevention of corneal endothelial cell
loss under pathological conditions andhelp tomake these cells less
susceptible to cellular stress. Indeed, further investigations are
necessary to corroborate this data, but our in vitrofindings suggest
that minocycline might offer properties that could potentially
prevent corneal endothelial cell loss in vivo.
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